Latest Breaking News On - தொற்று நோய் ஆராய்ச்சி நிறுவனம் - Page 2 : comparemela.com

New vaccine candidate could be a cost-effective option against emerging SARS-CoV-2 variants A multidisciplinary team of researchers is the first to show combining yeast-expression technology and a novel adjuvant formulation to produce a COVID-19 vaccine candidate is effective against SARS-COV-2 and promises to be easy to produce at large scale and cost-effective, important aspects for vaccinating people worldwide, especially in low- to middle-income countries. Results from the study, which applied lessons learned from the hepatitis b vaccine platform technology, are published online today in Science Immunology. Researchers from the Yerkes National Primate Research Center (NPRC) at Emory University, Infectious Disease Research Institute (IDRI), 3M and Texas Children s Hospital s Center for Vaccine Development at Baylor College of Medicine paired Baylor s SARS-CoV-2 Receptor Binding Domain (RBD) recombinant protein formulation vaccine candidate with IDRI s aluminum-based formulatio

Baylor college of medicineUnited statesRafickp sekalySudhir kasturiEmily hendersonPeter hotezMirko paiardiniMaria elena bottazziSusan pereira ribeiroChristopher foxMark tomaiEmory universityNational school of tropical medicine at baylorInfectious disease research instituteVaccine development at baylor college of medicineAlum group